

SUCCESSFUL COMPLETION OF DOSING IN FIRST PATIENT COHORT FOR PHASE 1 CLTX CAR T TRIAL

Chimeric Therapeutics, a clinical stage cell therapy company, is pleased to announce the successful completion of the planned dosing of the first patient cohort (n=4) in the phase 1 dose escalation study, evaluating the safety and maximum tolerated dose of Chimeric's Chlorotoxin CAR T (CLTX CAR T) in patients with recurrent or progressive glioblastoma (GBM).

The Phase 1 study aims to enroll 18-36 patients with MMP2+ recurrent or progressive GBM across 4 dose levels. Study objectives are to evaluate the safety and efficacy of CLTX CAR T and to establish recommended dosing for a phase 2 trial.

The dosing of this 4th patient marks the completion of planned dosing in the first and lowest dose level. Patients in this dose cohort were dosed via single site administration (intracranial intratumoral or intracavitary (ICT) administration) at a dose of 44×10^6 CLTX CAR T cells.

As this is a first in human phase 1 cell therapy trial, the 4 patients dosed within this first cohort received staggered treatment, in accordance with FDA guidance. Staggered treatment requires a follow up interval between the administration of the product to one patient and administration of the product to the next patient, essentially only allowing for sequential treatment of patients with an interval long enough to monitor for adverse events between the dosing of each patient.

As the final patient of this first dose cohort successfully completes the DLT period, the study will begin to recruit patients for the next dose level which will introduce dual administration (ICT administration and intracranial intraventricular (ICV) administration) at a dose of 88×10^6 CAR T cells.

Authorised on behalf of the Chimeric Therapeutics board of directors by Chairman Paul Hopper.

ABOUT CHLOROTOXIN CAR T

Chlorotoxin CAR T (CLTX CAR T) is a first and potentially best in class CAR T therapy that has the potential to address the high unmet medical need of patients with recurrent/ progressive glioblastoma.

CLTX CAR T uniquely utilizes chlorotoxin (CLTX), a peptide derived from scorpion toxin, as the tumour-targeting component of the chimeric antigen receptor (CAR) which has been shown in preclinical models to bind more broadly and specifically to GBM cells than other targeting domains like EGFR, HER-2 or IL-13.

In preclinical models, CLTX CAR T also demonstrated potent antitumor activity against glioblastoma while not exhibiting any off-tumor recognition of normal human cells/tissues, supporting a potentially optimal safety and efficacy profile.

ABOUT CHIMERIC THERAPEUTICS

Chimeric Therapeutics is a clinical stage cell therapy company focused on bringing the promise of cell therapy to life for more patients with cancer.

Chimeric believes that cellular therapies have the potential to cure cancer and that by combining their expertise in the development and commercialization of cell therapies with the world's most innovative scientists and science, they will be able to bring the promise of cell therapy to life for more patients.

Chimeric Therapeutics has the exclusive global rights to Chlorotoxin CAR T which is currently in development for patients with recurrent glioblastoma and is also being investigated for development in patients with other solid tumors such as melanoma, small cell lung cancer, prostate cancer and colorectal cancer.

Chimeric Therapeutics is also currently actively engaged in enhancing their pipeline with innovative cell therapies for patients with cancer.

CONTACT

Investors

Paul Hopper

Executive Chairman

P: +61 406 671 515

E: paulhopper@lifescienceportfolio.com

W: www.chimerictherapeutics.com

Media

Matthew Wright

NWR Communications

P: +61 451 896 420

E: matt@nwrcommunications.com.au